.gif)
Clore Laboratory: News
Diabetes, Obesity and Metabolic Research
7 July 2005 – Abstracts on novel antidiabetic compounds presented at ADA conference
Two posters on studies undertaken at the Clore Laboratory, University of Buckingham, UK, in collaboration with Prosidion Limited were presented at the 65th Scientific Sessions of the American Diabetes Association, held in San Diego, CA, USA, 10–14 June 2005.
Novel long and short acting glucokinase activators were shown to lower blood glucose in db/db mice and improve glucose tolerance in ZDF rats and ob/ob mice. There was no evidence of pharmacological tolerance in sub-chronic studies in ob/ob mice.
A novel allosteric inhibitor of glycogen phosphorylase which blocked glucagon-induced glycogenolysis in human hepatocytes with EC50 of 1.1µM was effective in lowering blood glucose in both ob/ob and db/db mice. In both models there was an increase in hepatic glycogen content. In a sub-chronic study in db/db mice there was no evidence of tolerance to the antidiabetic action over an 8 day dosing period.
The abstracts are published in a supplement of Diabetes as follows:
Fyfe MCT, Cawthorne MA, Sennitt MV, Printz RL. Antihyperglycemic effects of novel long- and short-acting glucokinase activators (PSN105 and PSN010) in diabetic animals. Diabetes 2005 54(Suppl 1): A129, Abs. 522-P
Wong-Kai-In P, Cawthorne MA, Wargent E, Thomas G. PSN357, a novel glycogen phosphorylase inhibitor with anti-hyperglycemic efficacy in rodent models of diabetes. Diabetes 2005 54(Suppl 1): A140, Abs. 567-P